January 6, 2015 — A study that identifies new heart attack risk factors and supports the use of a blood test for detection in patients will be published in the AACE (American Association of Clinical Endocrinologists) Journal.
“There is a great need to correctly identify individuals with active, yet undetected subclinical disease who are at risk of experiencing a coronary event, and for whom early intervention can help,” says Douglas Harrington, M.D., CEO of GD Biosciences and co-author of the study. “Most heart attacks occur at the site of a non-obstructive lesion and many patients do not have symptoms or abnormal lipids.”
GD Biosciences developed the new blood test to help identify patients at risk of suffering a heart attack.
“Inflammatory Biomarkers & Diabetes as Predictors of CHD in MESA” was also co-authored by Americo Simonini, M.D., attending cardiologist at Cedars Sinai Medical Center, Los Angeles. Simonini says exercise testing or cardiac imaging only diagnose higher-grade coronary stenosis, but fails to identify many at-risk patients who are not showing any symptoms.
The research finds that the use of nine biomarkers and established clinical risk factors (including diabetic status) correlated with the underlying formation of unstable cardiac lesions and significantly improved identification of at-risk patients frequently missed by current methods.
Results demonstrated that the novel protein-biomarker and clinical risk factor algorithm identified patients who went on to experience an acute coronary event. Acute Coronary Syndrome (ACS) is the main cause of coronary artery disease mortality. Insulin resistance and diabetes are significant factors increasing risk of ACS.
For more information: www.gdbiosciences.com
November 18, 2024 
